INTS Q3 EPS Decreased by Brookline Capital Markets

Intensity Therapeutics Inc. (NASDAQ:INTS) – Equities research analysts at Brookline Capital Markets reduced their Q3 2026 earnings per share estimates for shares of Intensity Therapeutics in a report issued on Friday, August 14th. Brookline Capital Markets analyst K. Raja now forecasts that the company will post earnings of ($0.77) per share for the quarter, down from their previous estimate of ($0.57). The consensus estimate for Intensity Therapeutics’ current full-year earnings is ($2.70) per share. Brookline Capital Markets also issued estimates for Intensity Therapeutics’ Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($3.41) EPS, FY2027 earnings at ($2.41) EPS, FY2028 earnings at ($6.01) EPS and FY2030 earnings at $13.27 EPS.

Intensity Therapeutics (NASDAQ:INTS) last announced its earnings results on Tuesday, August 11th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.24).

A number of other brokerages have also weighed in on INTS. Citigroup reaffirmed a “buy” rating on shares of Intensity Therapeutics in a research note on Tuesday, August 11th. Benchmark restated a “speculative buy” rating on shares of Intensity Therapeutics in a report on Wednesday, May 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $37.50.

Intensity Therapeutics Stock Up 4.8%

Shares of INTS stock opened at $4.15 on Tuesday. Intensity Therapeutics has a 12-month low of $3.51 and a 12-month high of $43.50. The company has a quick ratio of 5.00, a current ratio of 5.00 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average of $4.26 and a 200-day moving average of $5.48. The company has a market capitalization of $13.53 million, a price-to-earnings ratio of -0.73 and a beta of 2.76.

Institutional Investors Weigh In On Intensity Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mesirow Financial Investment Management Inc. boosted its stake in shares of Intensity Therapeutics by 25.5% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock worth $103,000 after buying an additional 51,000 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Intensity Therapeutics during the 4th quarter worth approximately $26,000. Corient Private Wealth LLC bought a new stake in shares of Intensity Therapeutics during the 4th quarter worth approximately $41,000. State Street Corp boosted its holdings in shares of Intensity Therapeutics by 839.3% in the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after buying an additional 121,700 shares during the last quarter. Finally, Legacy Advisors LLC bought a new position in shares of Intensity Therapeutics in the fourth quarter valued at $63,000. 3.74% of the stock is currently owned by institutional investors and hedge funds.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.